Veltassa: payments to doctors
Payments that named Veltassa as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6.1M
- Providers
- 13,372
- Transactions
- 80,072
- Average per transaction
- $76
The per-transaction average — $76 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 13,372 providers the average total is $457, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Relypsa, Inc. | $3,097,322 | 50.7% |
| Vifor Pharma, Inc. | $2,473,833 | 40.5% |
| Vifor (international) Ltd. | $458,434 | 7.5% |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | $79,077 | 1.3% |